Skip to main
VALN
VALN logo

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE reported a 13% year-over-year increase in product sales, totaling €163.3 million in 2024, compared to €144.6 million in 2023. The company’s total revenue reached €169.6 million in 2024, reflecting a 10% growth from €153.7 million in the previous year, supported by the recent accelerated approval of Ixchiq by the FDA, which is expected to significantly boost sales. Furthermore, Valneva anticipates Ixchiq sales will surpass €100 million by its third year on the market, with an estimated global market potential for chikungunya vaccines exceeding $500 million annually, underlining a strong future revenue outlook.

Bears say

Valneva SE has projected a significant reduction in its operating cash burn, targeting below €30 million in 2025, a decrease from over €60 million anticipated in 2024. Revenue estimates for 2025 have been revised downward from €222.5 million to €185 million, alongside a lowered earnings per share estimate changing from (€0.53) to (€0.65). Additionally, forecasts for Ixchiq sales have been decreased, with 2024 estimates at €3 million and 2029 estimates reduced from €250 million to €225 million, indicating ongoing challenges in revenue generation within the company's portfolio.

Valneva SE (VALN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.